BridgeBio Pharma Operating Expenses 2018-2024 | BBIO

BridgeBio Pharma operating expenses for the twelve months ending September 30, 2024 were $0.762B, a 34.03% increase year-over-year.

  • BridgeBio Pharma annual operating expenses for 2023 were $0.617B, a 4.55% increase from 2022.
  • BridgeBio Pharma annual operating expenses for 2022 were $0.59B, a 8.74% decline from 2021.
  • BridgeBio Pharma annual operating expenses for 2021 were $0.646B, a 33.89% increase from 2020.

BridgeBio Pharma Operating Expenses 2018-2024 | BBIO

  • BridgeBio Pharma annual operating expenses for 2023 were $0.617B, a 4.55% increase from 2022.
  • BridgeBio Pharma annual operating expenses for 2022 were $0.59B, a 8.74% decline from 2021.
  • BridgeBio Pharma annual operating expenses for 2021 were $0.646B, a 33.89% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M